Ventracor Limited Release: CE Submission At Final Stage -- Data ‘Very Encouraging’

Ventracor Limited (ASX: VCR) today said an early review of the clinical performance data for the VentrAssist during the CE Mark Trial was “very encouraging” and its submission to be made as part of the CE Mark approval process would show “strong performance statistically.”